176 related articles for article (PubMed ID: 903399)
21. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
22. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
23. Oestrogens, the menopause and the adrenopause.
Nordin BE; Crilly RG; Marshall DH; Barkworth SA
J Endocrinol; 1981; 89 Suppl():131P-143P. PubMed ID: 6453916
[No Abstract] [Full Text] [Related]
24. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
26. The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.
Santen RJ; Wells SA
Cancer; 1980 Aug; 46(4 Suppl):1066-74. PubMed ID: 6249490
[No Abstract] [Full Text] [Related]
27. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
28. Role of aminoglutethimide in male breast cancer.
Harris AL; Dowsett M; Stuart-Harris R; Smith IE
Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
30. Adrenal of male dog secretes androgens and estrogens.
Santen RJ; Samojlik E; Demers L; Badder E
Am J Physiol; 1980 Aug; 239(2):E109-12. PubMed ID: 7406039
[TBL] [Abstract][Full Text] [Related]
31. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
32. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
[TBL] [Abstract][Full Text] [Related]
33. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
34. Aminoglutethimide stimulates extra adrenal delta-4-androstenedione production.
Badder EM; Lerman S; Santen R
J Surg Res; 1983 Apr; 34(4):380-7. PubMed ID: 6834820
[No Abstract] [Full Text] [Related]
35. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; Zava D; Powles TJ
Cancer Res; 1982 Aug; 42(8 Suppl):3415s-3419s. PubMed ID: 6211228
[TBL] [Abstract][Full Text] [Related]
37. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of aminoglutethimide in breast cancer.
Santen RJ; Veldhuis J; Samojlik E; Lipton A; Harvey H; Wells SA
Lancet; 1979 Jan; 1(8106):44-5. PubMed ID: 83490
[No Abstract] [Full Text] [Related]
39. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
